Kitamura M, Kitaichi N, Takeuchi M, Kitamei H, Namba K, Yamagishi S-I, Iwabuchi K, Onoé K, Ohno S
Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Br J Ophthalmol. 2005 Nov;89(11):1407-9. doi: 10.1136/bjo.2005.072678.
BACKGROUND/AIMS: Advanced glycation end products (AGEs) are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease.
Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody.
The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p<0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p<0.001).
These results suggest that AGE-2 may be involved in the onset of VKH disease.
背景/目的：晚期糖基化终末产物（AGEs）被认为是与年龄相关的病理状况和糖尿病并发症的介质。最近有报道称，甘油醛衍生的AGE（AGE-2）对多种疾病具有强烈的生物学效应。本研究的目的是调查伏格特-小柳-原田病（VKH病）患者的血清AGE-2水平。
从31例活动期VKH病患者中获取血清。这31例患者中有20例接受了全身皮质类固醇治疗。作为对照，还检查了33名健康志愿者。使用AGE-2多克隆抗体通过竞争性酶联免疫吸附测定法测定血清AGE-2水平。
VKH病患者血清中的平均AGE-2水平为4.91（标准差2.23）U/ml，显著低于健康对照者（8.32（2.94），p<0.001）。患者接受全身皮质类固醇治疗后，血清AGE-2平均水平显著升高至13.49（2.17）U/ml（p<0.001）。
这些结果表明AGE-2可能与VKH病的发病有关。
